Carbapenem-resistant organisms (CRO) are an emerging threat to feline health and veterinary infection control. Although carbapenems are rarely used in cats, CRO, including carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA), are increasingly detected in hospitalized cats and have caused outbreaks in veterinary hospitals. These infections are associated with high morbidity, limited treatment options, and increased costs, and are an infection risk to pet owners and veterinary staff. Current knowledge gaps include the antimicrobial susceptibility of CREs and non-fermenting gram-negative bacteria (CRAB, CRPA) colonizing and infecting cats. This study aims to (1) identify effective, affordable, and ethically appropriate antimicrobials for treating CRE infections in cats by performing extended susceptibility testing on previously isolated feline CRE strains and comparing susceptibility of CRE colonizing strains to CRE infecting strains, and (2) characterize CRAB and CRPA colonizing hospitalized cats, including confirmation of carbapenem resistance and antimicrobial susceptibility profiling, and comparison to clinical strains infecting cats. By generating a feline-specific antibiogram for CRE, CRAB, and CRPA, this research will provide actionable data for veterinarians to guide treatment decisions and strengthen antimicrobial stewardship. These findings will fill a critical gap in feline medicine and support antimicrobial stewardship strategies that protect cats, veterinary staff, and pet owners.